Lane, N. E. http://orcid.org/0000-0002-0177-2198
Saag, K. http://orcid.org/0000-0001-6189-8078
O’Neill, T. J.
Manion, M.
Shah, R. http://orcid.org/0000-0002-7630-820X
Klause, U.
Eastell, R. http://orcid.org/0000-0002-0323-3366
Funding for this research was provided by:
Roche Diagnostics International Ltd and Roche Diagnostics Information Solutions
Article History
Received: 19 August 2020
Accepted: 5 November 2020
First Online: 24 November 2020
Change Date: 19 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00198-021-05828-3
Compliance with ethical standards
:
: N. Lane reports consultancy funding from Roche, and consultancy and speaker funding from Amgen. K. Saag reports grants from Amgen, Radius, and Mereo, and consultancy funding from Amgen, Daichi-Sankyo, and Roche. T. O’Neill is an employee of Roche Diagnostics Information Solutions and owner of stocks in Roche, Gilead, Pfizer, Regeneron, Abbott, and United Healthcare. M. Manion is an employee of Roche Diagnostics International Ltd. R. Shah is an employee of Roche Diagnostics International Ltd. and owner of stock in Roche. U. Klause is an employee of Roche Diabetes Care. R. Eastell reports consultancy funding from IDS, Sandoz, Nittobo, Roche Diagnostics, Samsung, Haoma Medica, CL Bio, Biocon, Lyramid, and Viking Therapeutics, and grant funding from Nittobo, Roche Diagnostics, and Alexion.
: All data were anonymized to comply with HIPAA and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Thus, Institutional Review Board approval was not required.
: Formal informed consent was not obtained.
: All authors consent to the publication of this study.
: Not applicable.